Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.

被引：16
|
作者：
Katz, Matthew H. G.
Varadhachary, Gauri R.
Bauer, Todd W.
Acquavella, Nicolas
Merchant, Nipun B.
Le, Tri Minh
Javle, Milind M.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4125
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Phase I study of veliparib with gemcitabine and radiation therapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer.
    Tuli, Richard
    Nissen, Nicholas N.
    Annamalai, Alagappan
    Hoffman, David M. J.
    Bryant, Miranda
    Tighiouart, Mourad
    Rogatko, Andre
    Rokhsar, Sepehr
    Scher, Kevin S.
    Jamil, Laith
    Lo, Simon
    Hendifar, Andrew Eugene
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [22] Phase II study of neoadjuvant durvalumab and tremelimumab in combination with gemcitabine and cisplatin in patients with intrahepatic cholangiocarcinoma that is borderline resectable or resectable with high risk for recurrence
    Sadagopan, Narayanan
    Weinberg, Benjamin Adam
    Noel, Marcus Smith
    Mukherji, Reetu
    Tesfaye, Anteneh A.
    Marshall, John
    Radkani, Pejman
    Guerra, Juan F.
    Nguyen, Brian M.
    Fishbein, Thomas M.
    He, Aiwu Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: BTS-NAC Study
    Saito, Kei
    Nakai, Yousuke
    Isayama, Hiroyuki
    Yamamoto, Ryuichi
    Kawakubo, Kazumichi
    Kodama, Yuzo
    Katanuma, Akio
    Kanno, Atsushi
    Itonaga, Masahiro
    Koike, Kazuhiko
    GUT AND LIVER, 2021, 15 (01) : 135 - 141
  • [24] Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
    Okada, Ken-Ichi
    Hirono, Seiko
    Kawai, Manabu
    Miyazawa, Motoki
    Shimizu, Atsushi
    Kitahata, Yuji
    Ueno, Masaki
    Hayami, Shinya
    Yamaue, Hiroki
    ANTICANCER RESEARCH, 2017, 37 (02) : 853 - 858
  • [25] Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm phase II study (NAC-GA trial)
    Okada, Ken-ichi
    Kimura, Kenjiro
    Yamashita, Yo-Ichi
    Shibuya, Kazuto
    Matsumoto, Ippei
    Satoi, Sohei
    Yoshida, Kazuhiro
    Kodera, Yasuhiro
    Akahori, Takahiro
    Hirono, Seiko
    Eguchi, Hidetoshi
    Asakuma, Mitsuhiro
    Tani, Masaji
    Hatano, Etsuro
    Ikoma, Hisashi
    Ohira, Go
    Hayashi, Hiromitsu
    Wan, Ke
    Shimokawa, Toshio
    Kawai, Manabu
    Yamaue, Hiroki
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2023, 7 (06): : 997 - 1008
  • [26] Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial
    Jang, Jin-Young
    Han, Youngmin
    Lee, Hongeun
    Kim, Sun-Whe
    Kwon, Wooil
    Lee, Kyung-Hun
    Oh, Do-Youn
    Chie, Eui Kyu
    Lee, Jeong Min
    Heo, Jin Seok
    Park, Joon Oh
    Lim, Do Hoon
    Kim, Seong Hyun
    Park, Sang Jae
    Lee, Woo Jin
    Koh, Young Hwan
    Park, Joon Seong
    Yoon, Dong Sup
    Lee, Lk Jae
    Choi, Seong Ho
    ANNALS OF SURGERY, 2018, 268 (02) : 215 - 222
  • [27] Phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation (RT) in patients with resectable (R) or borderline resectable (BR) pancreatic cancer
    Kim, E. J.
    Ben-Josef, E.
    Griffith, K. A.
    Herman, J. M.
    Wolfgang, C. L.
    Bekaii-Saab, T. S.
    Bloomston, M.
    Dawson, L. A.
    Moore, M. J.
    Zalupski, M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [28] Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study
    Hashimoto, Daisuke
    Satoi, Sohei
    Ishikawa, Hideki
    Kodera, Yasuhiro
    Kamei, Keiko
    Hirano, Satoshi
    Fujii, Tsutomu
    Uemura, Kenichiro
    Tsuchida, Akihiko
    Yamada, Suguru
    Yamamoto, Tomohisa
    Hirota, Kiichi
    Sekimoto, Mitsugu
    TRIALS, 2022, 23 (01)
  • [29] Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study
    Daisuke Hashimoto
    Sohei Satoi
    Hideki Ishikawa
    Yasuhiro Kodera
    Keiko Kamei
    Satoshi Hirano
    Tsutomu Fujii
    Kenichiro Uemura
    Akihiko Tsuchida
    Suguru Yamada
    Tomohisa Yamamoto
    Kiichi Hirota
    Mitsugu Sekimoto
    Trials, 23
  • [30] Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
    Goetze, Thorsten O.
    Reichart, Alexander
    Bankstahl, Ulli S.
    Pauligk, Claudia
    Loose, Maria
    Kraus, Thomas W.
    Elshafei, Moustafa
    Bechstein, Wolf O.
    Trojan, Joerg
    Behrend, Matthias
    Homann, Nils
    Venerito, Marino
    Bohle, Wolfram
    Varvenne, Michael
    Bolling, Claus
    Behringer, Dirk M.
    Kratz-Albers, Karsten
    Siegler, Gabriele M.
    Hozaeel, Wael
    Al-Batran, Salah-Eddin
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (06) : 4073 - 4083
12345